论文部分内容阅读
目的研究双环醇片联合胸腺肽治疗慢性乙型肝炎的疗效和安全性。方法随机选择135例慢性乙型肝炎患者分2组接受治疗,试验组,68例,每日口服双环醇片75mg,同时使用胸腺肽20mg,肌内注射,隔日一次,对照组,67例,仅给予每日口服双环醇片75mg,2组均连续用药24周。观察治疗前后血清氨基转移酶水平及血清病毒学标志方面的改变。结果2组血清氨基转移酶均得到明显下降,但差异无统计学意义。试验组HBeAg阴转率(35.3%)显著高于对照组(19.4%)P<0.05,HBeAg血清转换率(22.0%)虽高于对照组(14.9%),但差异无统计学意义,HBVDNA阴转率(36.7%)显著高于对照组(20.9%)P<0.05。2组均未出现明显不良反应。结论双环醇片和胸腺肽联合应用治疗慢性乙型肝炎可提高抗病毒疗效且安全。
Objective To study the efficacy and safety of bicyclic alcohol tablets combined with thymosin in the treatment of chronic hepatitis B patients. Methods One hundred and thirty-five patients with chronic hepatitis B were randomly divided into two groups. The experimental group, 68 cases, daily oral bicyclol tablets 75mg, thymosin 20mg, intramuscular injection, every other day, the control group, 67 cases, only given Daily oral bicyclol tablets 75mg, 2 groups were continuous medication for 24 weeks. Changes in serum aminotransferase levels and serum virological markers were observed before and after treatment. Results Serum aminotransferase in both groups were significantly decreased, but the difference was not statistically significant. The negative rate of HBeAg in the test group (35.3%) was significantly higher than that in the control group (19.4%) (P <0.05), while the HBeAg seroconversion rate was 22.0% (14.9%), but the difference was not significant Transfer rate (36.7%) was significantly higher than the control group (20.9%) P <0.05.2 no significant adverse reactions. Conclusion The combination of bicyclic alcohol tablets and thymosin in the treatment of chronic hepatitis B can improve the anti-virus efficacy and safety.